New antibody drug targets Hard-to-Treat lung cancers in early trial
NCT ID NCT07416695
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 138 adults aged 18 to 75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai Chest Hospital
NOT_YET_RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental cancer therapy targets tough tumors with radioactive precision
- New hope for tough lung cancer: Dual-Action drug combo in final testing
- New drug combo aims to outperform standard care in aggressive lung cancer
- Could a simple supplement help fragile preemies breathe easier?
- New hope for tough lung cancer: expanded access to targeted drug
- New PET scan probe could sharpen lung cancer detection